Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial

In the FIBRONEER-IPF trial, nerandomilast had no effect on the composite endpoint of time to first acute exacerbation, hospitalization for respiratory cause, or death, but nerandomilast 18 mg bid was associated with a numerically lower risk of death. Nerandomilast had a favorable safety profile, with a low rate of discontinuation due to adverse events.

Authors

Institutions

Publication Details

Journal
American Journal of Respiratory and Critical Care Medicine
Published
2026-02-11
DOI
https://doi.org/10.1093/ajrccm/aamag058
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial

Diane Zisa, Y. Liu, Donald F. Zoz, Luca Richeldi et al.
American Journal of Respiratory and Critical Care Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial

Diane Zisa, Y. Liu, Donald F. Zoz, Luca Richeldi, Fernando J. Martinez, FIBRONEER-IPF trial investigators, Justin M Oldham, Vincent Cottin, Arata Azuma, Marlies S Wijsenbeek, Michael Kreuter, Claudia Valenzuela, Toby M Maher
article en

Abstract

In the FIBRONEER-IPF trial, nerandomilast had no effect on the composite endpoint of time to first acute exacerbation, hospitalization for respiratory cause, or death, but nerandomilast 18 mg bid was associated with a numerically lower risk of death. Nerandomilast had a favorable safety profile, with a low rate of discontinuation due to adverse events.

American Journal of Respiratory and Critical Care Medicine
Université Claude Bernard Lyon 1 (FR), Università Cattolica del Sacro Cuore (IT), University of Southern California (US), UMass Memorial Health Care (US), Johannes Gutenberg University Mainz (DE), University of Michigan (US), Erasmus MC (NL), Agostino Gemelli University Polyclinic (IT), University Medical Center of the Johannes Gutenberg University Mainz (DE), Lung Institute (US), Boehringer Ingelheim (Brazil) (BR), Michigan Medicine (US), Boehringer Ingelheim (Japan) (JP), Hospital Universitario de La Princesa (ES), Hôpital Louis Pradel (FR), Boehringer Ingelheim (France) (FR), Nobuhara Hospital (JP), Boehringer Ingelheim (Spain) (ES), UMass Memorial Medical Center (US), Universidad Autónoma de Madrid (ES), Nippon Medical School (JP), Erasmus University Rotterdam (NL)
Openalex Percentile: Top 47%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial — Diane Zisa, Y. Liu, et al. · American Journal of Respiratory and Critical Care Medicine (2026) | TGRS Research Map | TGRS